Kymera Therapeutics stockKYMR
Kymera Therapeutics trades at $128.12, 7.2% below its 52-week high (Nov 5, 2026). The price is above its 50- and 200-day averages, i.e. in an uptrend. +64.7% year to date, +113.9% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Feb 25, 2027.
No news on Kymera Therapeutics today. Its industry peers (Biotechnology) that day: “Post-midterm AI selloff drags Twist Bioscience 15% lower alongside high-beta genomics peers”.
All moves of the day →Ratings, candles, signals and the screener for KYMR — after you log in
Open the terminalFrequently asked questions about Kymera Therapeutics
What is the Kymera Therapeutics stock price?
At the close on Nov 5, 2026: $128.12 (−5.97% on the day). 52-week high: $138.00 on Nov 5, 2026. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Kymera Therapeutics report earnings?
The next quarterly report is on Feb 25, 2027. Last quarter, earnings per share changed −40% year over year, revenue −100%.
Does Kymera Therapeutics pay dividends?
No, Kymera Therapeutics does not pay dividends.
Where does Kymera Therapeutics trade and how to buy it?
Ticker KYMR, exchange Nasdaq, listed since 2020. You can buy it through a broker with access to US exchanges.
Should I buy Kymera Therapeutics now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for KYMR are in the terminal after you log in.